2026, Volume 33, Supplement 1:
Sponsorship statement: The development of this white paper was organised and fully funded by Pfizer Ltd. Pfizer Ltd also organised and funded the publication of this work as a supplement to the British Journal of Cardiology.
PP-UNP-GBR-14528 | May 2026
2024, Volume 31, Supplement 1:
2024, Volume 31, Supplement 2:
2024, Volume 31, Supplement 3:
2023, Volume 30, Supplement 1:
2023, Volume 30, Supplement 2:
2023, Volume 30, Supplement 3:
2022, Volume 29, Supplement 2:
2021, Volume 28, Supplement 1:
2020, Volume 27, Supplement 1:
2020, Volume 27, Supplement 2:
2019, Volume 26, Supplement 1:
2019, Volume 26, Supplement 2:
2018, Volume 25, Supplement 1:
2018, Volume 25, Supplement 2:
2018, Volume 25, Supplement 3:
2017, Volume 24, Supplement 1:
2016, Volume 23, Supplement 1:
2016, Volume 23, Supplement 2:
2015, Volume 22, Supplement 1:
2014, Volume 21, Supplement 1:
2014, Volume 21, Supplement 2:
2013, Volume 20, Supplement 1:
2013, Volume 20, Supplement 2:
2012, Volume 19, Supplement 2:
2011, Volume 18, Supplement 1:
2010, Volume 17, Supplement 1:
2010, Volume 17, Supplement 2:
2010, Volume 17, Supplement 3:
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits
